Table 1.
Demographic and clinical characteristics by colorectal cancer (CRC) case group*
|
Type 1
MSI-high, BRAF- mutated, KRAS- mutation negative, CIMP-positive (N=100, 7%) |
Type 2
MSS/MSI-low, BRAF- mutated, KRAS- mutation negative, CIMP-positive (N=55, 4%) |
Type 3
MSS/MSI-low, BRAF-mutation negative, KRAS- mutated, non-CIMP (N=353, 26%) |
Type 4
MSS/MSI-low, BRAF- & KRAS- mutation negative, non-CIMP (N=631,47%) |
Type 5
MSI-high, BRAF- & KRAS-mutation negative, non- CIMP (N=50, 4%) |
Other
(N=155, 12%) |
Unknown†
(N=706) |
X2
p- value |
|
|---|---|---|---|---|---|---|---|---|
| Age at diagnosis | ||||||||
| Mean (SD) | 67.3 (5.3) | 63.6 (8.4) | 61.4 (9.0) | 60.1 (9.8) | 56.0 (12.2) | 60.7 (10.9) | 52.4 (12.1) | |
| <40 | 0 (0) | 1 (2) | 5 (1) | 22 (3) | 5 (10) | 8 (5) | 87 (12) | <0.01 |
| 40-49 | 1 (1) | 2 (4) | 37 (10) | 59 (9) | 10 (20) | 13 (8) | 292 (41) | |
| 50-59 | 7 (7) | 11 (20) | 93 (26) | 201 (32) | 15 (30) | 39 (25) | 102 (14) | |
| 60-69 | 51 (51) | 27 (49) | 140 (40) | 222 (35) | 10 (20) | 58 (37) | 137 (19) | |
| ≥70 | 41 (41) | 14 (25) | 78 (22) | 127 (20) | 10 (20) | 37 (24) | 88 (12) | |
| Sex | ||||||||
| Male | 17 (17) | 16 (29) | 149 (42) | 333 (53) | 21 (42) | 71 (46) | 318 (45) | <0.01 |
| Female | 83 (83) | 39 (71) | 204 (58) | 298 (47) | 29 (58) | 84 (54) | 388 (55) | |
| Race | ||||||||
| White | 95 (95) | 52 (95) | 318 (90) | 575 (91) | 43 (86) | 145 (94) | 471 (67) | 0.05 |
| African-American | 2 (2) | 3 (5) | 9 (3) | 27 (4) | 3 (6) | 1 (1) | 19 (3) | |
| Asian | 2 (2) | 0 (0) | 16 (5) | 11 (2) | 2 (4) | 3 (2) | 18 (3) | |
| >1 race | 1 (1) | 0 (0) | 6 (2) | 2 (0.3) | 0 (0) | 2 (1) | 9 (1) | |
| Other / Unknown | 0 (0) | 0 (0) | 4 (1) | 16 (3) | 2 (4) | 4 (3) | 189 (27) | |
| CRC family history | ||||||||
| No | 85 (85) | 47 (85) | 295 (84) | 538 (85) | 33 (66) | 128 (83) | 596 (84) | 0.02 |
| Yes | 15 (15) | 8 (15) | 58 (16) | 93 (15) | 17 (34) | 27 (17) | 110 (16) | |
| Stage at diagnosis | ||||||||
| I | 47 (47) | 11 (20) | 132 (38) | 281 (45) | 25 (50) | 60 (39) | 257 (37) | <0.01 |
| II-III | 52 (52) | 37 (67) | 174 (49) | 282 (45) | 24 (48) | 85 (55) | 338 (48) | |
| IV | 1 (1) | 7 (13) | 46 (13) | 66 (10) | 1 (2) | 10 (6) | 107 (15) | |
| Unknown | 0 | 0 | 1 | 2 | 0 | 0 | 4 | |
| 1st treatment course | ||||||||
| Received chemo | 44 (46) | 37 (71) | 203 (59) | 344 (67) | 24 (50) | 88 (59) | 435 (63) | 0.05 |
| No chemo | 52 (54) | 15 (29) | 142 (41) | 271 (33) | 24 (50) | 62 (41) | 256 (37) | |
| Unknown | 4 | 3 | 8 | 16 | 2 | 5 | 15 | |
| Tumor site | ||||||||
| Right colon: | 93 (93) | 43 (80) | 136 (39) | 132 (22) | 42 (84) | 111 (73) | 250 (36) | <0.01 |
| Cecum | 36 | 17 | 72 | 54 | 20 | 38 | 81 | |
| Ascending colon | 33 | 17 | 33 | 30 | 11 | 37 | 82 | |
| Hepatic flexure | 11 | 2 | 9 | 10 | 3 | 11 | 25 | |
| Transverse colon | 11 | 6 | 19 | 31 | 8 | 19 | 41 | |
| Splenic flexure | 2 | 1 | 3 | 13 | 0 | 6 | 21 | |
| Left colon: | 6 (6) | 9 (17) | 102 (29) | 218 (35) | 4 (8) | 18 (12) | 187 (27) | |
| Descending colon | 2 | 0 | 19 | 22 | 0 | 7 | 26 | |
| Sigmoid colon | 4 | 9 | 83 | 196 | 4 | 11 | 161 | |
| Rectal: | 1 (1) | 2 (4) | 112 (32) | 268 (43) | 4 (8) | 24 (16) | 258 (37) | |
| Rectosigmoid Junction | 1 | 1 | 28 | 67 | 2 | 8 | 61 | |
| Rectum | 0 | 1 | 84 | 201 | 2 | 16 | 197 | |
| Unknown | 0 | 0 | 3 | 7 | 0 | 2 | 2 | |
| MSI status | ||||||||
| MSS/MSI-L | 0 (0) | 55 (100) | 353 (100) | 631 (100) | 0 (0) | 84 (54) | 535 (86) | -- |
| MSI-H | 100 (100) | 0 (0) | 0 (0) | 0 (0) | 50 (100) | 71 (46) | 85 (14) | |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 86 | |
| BRAF-mutation status | ||||||||
| Wildtype | 0 (0) | 0 (0) | 353 (100) | 631 (100) | 50 (100) | 118 (76) | 533 (92) | -- |
| Mutated | 100 (100) | 55 (100) | 0 (0) | 0 (0) | 0 (0) | 37 (24) | 51 (8) | |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 102 | |
| KRAS-mutation status | ||||||||
| Wildtype | 100 (100) | 55 (100) | 0 (0) | 631 (100) | 50 (100) | 75 (48) | 396 (72) | -- |
| Mutated | 0 (0) | 0 (0) | 353 (100) | 0 (0) | 0 (0) | 80 (52) | 154 (28) | |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 156 | |
| CIMP status | ||||||||
| Non-CIMP | 0 (0) | 0 (0) | 353 (100) | 631 (100) | 50 (100) | 71 (46) | 127 (77) | -- |
| CIMP-positive | 100 (100) | 55 (100) | 0 (0) | 0 (0) | 0 (0) | 84 (54) | 37 (23) | |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 542 | |
| 5-yr survival (%) | ||||||||
| Overall | 80.5 | 46.2 | 67.8 | 78.0 | 84.1 | 71.8 | 75.3 | |
| Disease-specific | 89.5 | 49.2 | 72.4 | 82.5 | 93.1 | 79.7 | 78.7 |
*
Cases missing data on all 4 markers used in subtype classification are excluded from all analyses (N=616).
†
Cases of “unknown” subtype have missing data on 1 to 3 markers used in subtype classification and are re-allocated to subtype groups through multiple imputation in analyses.